Mdxhealth's New Share Capital Amount and New Number of Shares
August 19 2022 - 3:00PM
Mdxhealth's New Share Capital Amount and New Number of Shares
NEWS RELEASE - REGULATED
INFORMATIONAugust
19, 2022,
4:00 PM EDT / 22:00 CET
Mdxhealth's New Share
Capital Amount and New Number of
Shares
IRVINE, CA, and HERSTAL,
BELGIUM – August 19, 2022 – MDxHealth SA (NASDAQ/Euronext:
MDXH) ("mdxhealth" or the
"Company"), a commercial-stage precision
diagnostics company, today a announces, in accordance with Article
15 of the Belgian Act of May 2, 2007 on the disclosure of major
participations in issuers of which shares are admitted to trading
on a regulated market and regarding miscellaneous provisions, that
in the context of a capital increase completed on August 11, 2022
to settle a portion of the purchase price for the acquisition by
the Company of the Oncotype DX® GPS (Genomic Prostate Score®) test
from Genomic Health, Inc. (a subsidiary of Exact Sciences
Corportation) announced on August 2, 2022, its share capital has
increased from EUR 118,662,067.69 to EUR 123,539,165.19 and the
number of issued and outstanding shares has increased from
155,969,226 to 162,880,936 ordinary shares, through the issuance of
a total of 6,911,710 new shares. In addition to the outstanding
shares, the total number of outstanding subscription rights on the
moment of this press release amounts to 14,013,030, which entitles
their holders (assuming all subscription rights are granted and
exercised) to subscribe to 14,013,030 new shares with voting rights
in total.
About
mdxhealth®
Mdxhealth is a commercial-stage precision
diagnostics company that provides actionable molecular diagnostic
information to personalize the diagnosis and treatment of cancer.
The Company's tests are based on proprietary genetic, epigenetic
(methylation) and other molecular technologies and assist
physicians with the diagnosis of urologic cancers and prognosis of
recurrence risk. The Company’s European headquarters are in
Herstal, Belgium, with laboratory operations in Nijmegen, The
Netherlands, and U.S. headquarters and laboratory operations based
in Irvine, California, with additional laboratory operations in
Plano, Texas. For more information, visit mdxhealth.com and follow
us on social media at: twitter.com/mdxhealth,
facebook.com/mdxhealth and linkedin.com/company/mdxhealth.
For more information:
|
mdxhealth info@mdxhealth.com |
|
| LifeSci
Advisors (IR & PR)US:
+1-949-271-9223ir@mdxhealth.com |
|
Important
information
The mdxhealth logo, mdxhealth, Confirm mdx,
Select mdx, and Genomic Prostate Score are trademarks or registered
trademarks of MDxHealth SA. Oncotype DX and Exact Sciences are
trademarks of Exact Sciences Corporation. All other trademarks and
service marks are the property of their respective owners.
Mdxhealth (LSE:0O8G)
Historical Stock Chart
From Jan 2025 to Feb 2025
Mdxhealth (LSE:0O8G)
Historical Stock Chart
From Feb 2024 to Feb 2025
